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Identification of a Novel Polyamine
Scaffold With Potent Efflux Pump
Inhibition Activity Toward Multi-Drug
Resistant Bacterial Pathogens
Renee M. Fleeman1, Ginamarie Debevec2, Kirsten Antonen1, Jessie L. Adams1,
Radleigh G. Santos2, Gregory S. Welmaker2, Richard A. Houghten2, Marc A. Giulianotti2
and Lindsey N. Shaw1*
1 Department of Cell Biology, Microbiology and Molecular Biology, University of South Florida, Tampa, FL, United States,
2 Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL, United States
We have previously reported the use of combinatorial chemistry to identify broad-
spectrum antibacterial agents. Herein, we extend our analysis of this technology toward
the discovery of anti-resistance molecules, focusing on efflux pump inhibitors. Using
high-throughput screening against multi-drug resistant Pseudomonas aeruginosa,
we identified a polyamine scaffold that demonstrated strong efflux pump inhibition
without possessing antibacterial effects. We determined that these molecules were
most effective with an amine functionality at R1 and benzene functionalities at R2
and R3. From a library of 188 compounds, we studied the properties of 5 lead
agents in detail, observing a fivefold to eightfold decrease in the 90% effective
concentration of tetracycline, chloramphenicol, and aztreonam toward P. aeruginosa
isolates. Additionally, we determined that our molecules were not only active toward
P. aeruginosa, but toward Acinetobacter baumannii and Staphylococcus aureus as
well. The specificity of our molecules to efflux pump inhibition was confirmed using
ethidium bromide accumulation assays, and in studies with strains that displayed varying
abilities in their efflux potential. When assessing off target effects we observed no
disruption of bacterial membrane polarity, no general toxicity toward mammalian cells,
and no inhibition of calcium channel activity in human kidney cells. Finally, combination
treatment with our lead agents engendered a marked increase in the bactericidal
capacity of tetracycline, and significantly decreased viability within P. aeruginosa biofilms.
As such, we report a unique polyamine scaffold that has strong potential for the future
development of novel and broadly active efflux pump inhibitors targeting multi-drug
resistant bacterial infections.
Keywords: efflux pumps, efflux pump inhibitors, polyamines, bacterial resistance, potentiation
INTRODUCTION
The continued increase of antimicrobial resistant bacterial infections is an ongoing public health
crisis in the United States, with mortality rates increasing yearly (Boucher et al., 2009). This
problem can be directly linked to ever growing demands for antibiotics, coupled with a diminishing
therapeutic arsenal that has been exacerbated by a continual decline in antibiotic discovery over
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the past 30 years (Spellberg et al., 2008). This presents the
scenario of a much talked about post-antibiotic era, where
conventional antibiotics will no longer be effective and common
infections may once again become fatal (Reardon, 2014).
A primary issue is that typical drug discovery efforts often result
in the development of therapeutics with known mechanisms
of action, thus allowing bacteria to rapidly evolve resistance to
these new agents (Falagas and Bliziotis, 2007). Consequently,
new strategies are urgently needed for the discovery of novel
therapeutics targeting multi-drug resistant organisms (Spellberg
et al., 2008; Reardon, 2014).
The selective pressure antibiotics place on heterogeneous
bacterial communities often directly leads to resistant clones
becoming dominant within infectious populations (Spellberg
et al., 2008). Novel therapeutics targeting resistant bacterial
strains would be therapeutically advantageous, specifically
focusing on those isolates that prove the most difficult to
eradicate. A unique way to do this is to interfere with
bacterial resistance mechanisms, rather than focusing on
bacterial viability. Such treatment options could restore the
effectiveness of numerous obsolete clinical antibiotics, reclaiming
many important therapeutics. Co-administration of such anti-
resistance agents alongside existing antibiotics may also lead
to decreased resistance, as multiple targets within the cell are
impacted simultaneously (Yoneyama and Katsumata, 2014).
Hence, anti-resistance approaches may exponentially increase the
number of available therapeutic options, whereas conventional
antibiotic development commonly yield only a single new drug
(Renau et al., 1999; Lomovskaya et al., 2001).
A primary method by which bacteria resist the action of
antibacterial agents is via efflux pump extrusion. Efflux pumps are
complexes within the bacterial cell envelope used to export toxic
substances such as antibiotics from the intracellular environment
before damage to the cell occurs (Sun et al., 2014). Efflux pumps
are found in most multi-drug resistant nosocomial pathogens,
with many having similar and overlapping substrate specificities.
As such, targeting bacterial efflux pumps via therapeutic
intervention could effectively re-sensitize cells to a broad
spectrum of antibacterial agents (Renau et al., 1999; Lomovskaya
et al., 2001; Weinstein and Hooper, 2005). Indeed, recent studies
have shown that strains overexpressing efflux pumps commonly
display an average >twofold increased minimal inhibitory
concentrations (MIC) toward multiple antibiotics (Weinstein
and Hooper, 2005; Adabi et al., 2015).
Efflux mediated resistance was first described almost 40 years
ago in a study demonstrating that tetracycline insensitivity
could result from plasmid-encoded transport systems (McMurry
et al., 1980). Following this, Nelson et al. (1993, 1994) and
Nelson and Levy (1999) observed that polyamine tetracycline
derivatives could increase the effectiveness of tetracycline when
administered concomitantly. Early inhibitors targeting efflux
pumps, such as reserpine, were discovered from existing drugs,
however their use was limited by the need for administration
at very high doses in order to be effective (Van Bambeke
et al., 2006). They also suffered from off-target effects, with
compounds such as verapamil, reserpine, and thioridazine
not only inhibiting bacterial efflux pumps, but eukaryotic
transporters as well (Cornwell et al., 1987; Neyrolles et al., 2016).
Specifically, molecules such as verapamil when administered
at higher doses have been shown to cause cardiac arrest due
to calcium channel inhibition (Chevalier et al., 1999). More
recent agents, such as MC-207,110 (phenylalanine arginine
beta naphthalimide, or PaβN), have been shown to have
increased specificity toward bacterial efflux systems, (Renau
et al., 1999; Lomovskaya et al., 2001; Misra and Bavro, 2009;
Opperman and Nguyen, 2015); however, the advancement of
this scaffold has been abandoned as it has been shown to
non-specifically depolarize prokaryotic membranes and cause
significant nephrotoxicity (Watkins et al., 2003; Webber et al.,
2013; Opperman and Nguyen, 2015). Although a number
of efflux pump inhibitors with improved activity have been
identified in recent years (Chamberland et al., 1996, 1999, 2000,
2001; Zelle and Harding, 1996; Levy, 1998; Zelle, 1998; Markham
et al., 2000; De Souza et al., 2002; Nakayama et al., 2002; Pages
et al., 2003; Nelson and Alekhsun, 2004; Lemaire et al., 2006),
the only advancement into clinical trials to date has been for
the proton pump inhibitor omeprazole, used in combination
with amoxicillin and clarithromycin to treat Helicobacter pylori
infections (Handzlik et al., 2013; ClinicalTrials.gov, 2014).
Therefore, there is a clear need to identify new efflux pump
inhibitors with enhanced properties, and limited toxicity. This is
particularly true for Gram negative species, such as Pseudomonas
aeruginosa, which have impermeable outer membranes and
commonly overexpress efflux systems (Palmer and Whiteley,
2015; Tommasi et al., 2015). Indeed, this organism has
10 resistance nodulation division (RND) efflux pumps that
collectively extrude β-lactams, fluoroquinolones, sodium dodecyl
sulfate, tetracycline, erythromycin, ethidium bromide, crystal
violet, and homoserine lactones (Askoura et al., 2011). Moreover,
given the broad substrate range of P. aeruginosa efflux pumps,
the inhibition of one pump can be alleviated by the upregulation
of additional efflux pumps with parallel targets (Lister et al.,
2009).
In previous work by our group we used combinatorial
chemistry to identify broad spectrum antibacterial agents
(Fleeman et al., 2015; Sandhaus et al., 2016). In the present study,
we extend our analysis of this technology toward the discovery
of anti-resistance agents, specifically focusing on efflux pump
inhibitors. Using high throughput combinatorial scaffold library
screening against multi-drug resistant P. aeruginosa isolates we
identified a polyamine scaffold derived from a reduced acyl
peptide that demonstrated strong efflux pump inhibition and
limited cytotoxicity toward eukaryotic cells. We suggest that these
molecules possess excellent potential for future development as
anti-resistance agents targeting bacterial efflux pumps.
MATERIALS AND METHODS
Design and Synthesis of the
Combinatorial Libraries
The design and synthesis of the Torrey Pines scaffold ranking
library has previously been described (Houghten et al.,
1999; Reilley et al., 2010; Santos et al., 2013; Wu et al.,
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2013). The library is comprised of 84 different scaffolds,
each with 10,000–750,000 compounds, in approximately
equal molar amounts. The polyamine library chosen for
analysis contains 399,766 analogs; from this, 188 individual
compounds were chosen for analysis. Detailed chemical
characterization for scaffold libraries and individual compounds
can be found in the general chemistry method section in
Supplementary Figure S1. Individual compounds were
synthesized as described in Scheme a in Supplementary
Figure S1.
Bacterial Strains and Growth Conditions
The bacterial strains used in this study are multi-drug
resistant clinical isolates that have previously been described
(Supplementary Table S1; Fleeman et al., 2015). Organisms were
grown in tryptic soy broth (TSB) for overnight cultures and
cation adjusted Mueller Hinton broth (CA-MH II) was used
for experimental procedures. All incubations were performed
at 37◦C. The minimum inhibitory concentrations (MICS) for
all antibiotics tested against these organisms are shown in
Supplementary Table S1.
Checkerboard Potentiation Assays
Scaffold ranking library samples and individual polyamines
were screened using checkerboard inhibitory assays to assess
the potentiation of tetracycline and chloramphenicol. The
test utilized a 96-well plate microtiter assay where the
concentration of the scaffold or individual polyamine was
decreased from 25 to 0.8 µg mL−1 (average molarity of
mixture samples 65 to 4 µM) along the rows, and the
concentration of tetracycline or chloramphenicol was increased
from 0.4 to 100 µM across the columns. The EC90 values
for all polyamines are reported in µg mL−1 which more
accurately displays the effective concentrations for mixture
samples. However, with the known antibiotics, we report
EC90 values in µM, which more accurately describes purified
compounds. Plates were incubated statically at 37◦C for
20 h, and the optical density (OD600) was determined using
a Synergy 2 plate reader (BioTek). Potentiation modeling
(detailed below) was performed to determine fold change in
the 50 and 90% effective concentration of tetracycline or
chloramphenicol.
Statistical Analysis of Checkerboard
Assays
Potentiation was quantified using a mathematical model
developed by our group to assess the ability of library samples
and individual compounds to effectively enhance the activity
of tetracycline or chloramphenicol (Hoel, 1987). This was
used to differentiate libraries or compounds that possessed
only antibacterial activity from those that had synergistic
activity with tetracycline or chloramphenicol. In this way,
only libraries and compounds that potentiated tetracycline or
chloramphenicol activity were pursued. The model is based
on the following equation for modeling the percentage activity
of a mixture of two agents with independent action (Hoel,
1987):
%Antibiotic & Comp (x1, x2)
=%Antibiotic (x1)+%Comp (x2)−%Antibiotic (x1) ·%Comp (x2)
Here, x1 and x2 are the concentrations of antibiotic
(tetracycline or chloramphenicol) and library/compound
(Comp) tested, respectively. This equation can be
rearranged to model the effective percent activity (EC)
of the antibiotic alone, after accounting for compound
activity:
Eff%Antibiotic(x1)=
%Antibiotic & Compound(x1, x2)−%Compound(x2)
1−%Compound(x2)
Thus, the model-adjusted checkerboards show the antibiotic
activity post-potentiation, and from that one can determine the
true change in Mic.
Ethidium Bromide Efflux Inhibition Assay
Ethidium bromide efflux assessment was performed by following
the fluorescence of ethidium bromide in a 96-well plate assay,
as described previously (Renau et al., 1999; Lomovskaya et al.,
2001; Webber et al., 2013; Blanchard et al., 2014; Vasudevan
et al., 2014). This varies from ethidium bromide accumulation
assays as it includes a pre-incubation step to allow accumulation
before assessment of efflux (Raherison et al., 2002; Paixao et al.,
2009). Bacterial cells were grown overnight at 37◦C in TSB,
before being synchronized for 3 h in fresh media to exponential
phase. Cultures were pelleted at 900 × g for 20 min and the
supernatant removed. The resulting pellet was thrice washed and
resuspended in 20 mM sodium phosphate buffer to an OD600
of 0.2. Ethidium bromide was next added at a sub inhibitory
concentration of 25 µM and incubated at room temperature for
15 min to equilibrate. After equilibration, cells were inoculated
into a black walled 96-well plate to a density of 1 × 106 CFU
mL−1. Using a Biotek plate reader, the fluorescence of cells
was monitored for 2 min with 530 nm excitation and 600 nm
emission. When baseline readings were complete, polyamines
247, 250, 266, 271, and 314 were added at 25 µg mL−1 alongside
the positive control PaβN at the same concentration [all efflux
pumps inhibitor concentrations were maximum potentiating
concentrations (MPC)]. The solvent dimethylformamide (DMF)
was used as a no treatment control alongside tetracycline alone.
After addition of all compounds, fluorescence was monitored
every 5 min for a total of 90 min. After this time, cells
were serially diluted and plated to ensure that treatment with
ethidium bromide did not affect viability. There was an initial
spike in fluorescence upon addition of the compound, with
minimal changes observed thereafter, therefore for graphical
representation, the final maximum relative fluorescence at 90 min
was used for comparison of lead agents to controls.
Bacterial Membrane Depolarization
To determine the level of membrane depolarization by polyamine
compounds a 3,3′-dipropylthiadicarbocyanine Iodide (DiSC3)
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fluorescence dye was used. Exponentially growing cultures
were prepared as described above, before being harvested by
centrifugation. Cells were next washed in buffer a [5 mM Hepes
(pH 7.2), 5 mM glucose] and resuspended to an OD600 of
0.2 in the same buffer containing 100 mM KCL and 2 µM
DiSC3. Samples were allowed to equilibrate for 15 min at room
temperature to ensure uptake and quenching of the dye in
bacterial membranes. Cells were aliquoted into 96-well plates
and polyamines were added alongside the known efflux inhibitor
PAβN (all at 25 µg mL−1). Nisin (25 µg mL−1) was used as a
positive control to display depolarization effects. A Biotek plate
reader was used to monitor fluorescence of wells, with a 622 nm
excitation and 670 nm emission. For graphical representation, the
maximum relative fluorescence at 2 min was used for comparison
of lead agents to controls.
Eukaryotic Cell Cytotoxicity
To assess toxicity of polyamine compounds we used HepG2
human liver carcinoma cells and Hek293T human embryonic
kidney epithelial cells. The viability of cell lines was determined
using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) molecular probe as previously described by our
group (Fleeman et al., 2015). Briefly, 247, 266, 271 (Hek293T), or
250, 271, 314 (HepG2), alongside control efflux pump inhibitor
PaβN, were diluted in 10% DMF from 25 µg mL−1 to 3 µg mL−1
using twofold dilutions, before being added to cells in DMEM
with 10% FBS and 1% penicillin/streptomycin. Cells were then
incubated for 48 h at 37◦C with 5% CO2. Following this, viability
was assessed by the addition of MTT and measuring the OD570
in a Biotek plate reader. Percent recovery was determined
compared to no drug controls.
Eukaryotic Calcium Channel Activity
Assay
The effects of polyamine efflux inhibitors on eukaryotic ion
channels was performed using a calcium channel assay kit
(Life Technologies) and the Hek293T kidney cell line. Cells
(5 × 104) were inoculated into a black walled 96-well plate
and allowed to attach overnight at 37◦C with 5% CO2. After
this, the Fluo-4 dye supplemented with Probenecid (5 mM)
was added and allowed to equilibrate for 1 h at 37◦C with 5%
CO2. After this time, fluorescence was measured for 120 s using
a Biotek plate reader with a 495 nm excitation and 516 nm
emission. Cells were then treated with solvent only controls
(10% DMF), as well as polyamine compounds 250, 266, 271,
and the known calcium channel inhibitor verapamil (all at
25 µg mL−1). Fluorescence was monitored for 120 s, before
calcium channels were stimulated with carbamylcholine chloride
(137 µM). Readings were then taken at 6 s intervals, with peak
relative fluorescence at 18 s used graphically for comparison of
lead agents to controls.
Bactericidal and Biofilm Assessment
Lead agents were screened for bactericidal activity as described
by us previously (Van Horn et al., 2014; Fleeman et al., 2015),
with the following modifications. Varying concentrations of
tetracycline (0, 12, 25, and 50 µM) were used in combination
with the MPC (25 µM) of lead agents 247, 250, 266, 271,
and 314 against P. aeruginosa. Data is shown as percent
recovery by dividing the CFU mL−1 of treatment groups by
the CFU mL−1 recovered from a no treatment control that did
not have tetracycline or efflux inhibitors. Biofilm experiments
were performed similar to those described by us previously
(Fleeman et al., 2015; von Salm et al., 2016), with the following
modifications. Polyamine agents 247, 250, 266, 271, and 314 were
added at MPC into biofilm containing wells alongside varying
concentrations of tetracycline (0, 12, 25, and 50 µM). Cellular
viability was determined by serial dilution after a 20-h incubation
at 37◦C. Values were converted to percent recovery using no
treatment controls. All data was generated from three biological
replicates and two technical replicates.
RESULTS
The Use of a Scaffold Ranking Library to
Identify Potential Efflux Pump Inhibitors
We have previously described the synthesis and antibacterial
activity of the Torrey Pines scaffold ranking library toward
the ESKAPE pathogens. With the success of this screening, we
decided to expand our approaches toward the development of
anti-resistance agents, specifically targeting efflux mechanisms
(Fleeman et al., 2015). As such, the 81 Torrey Pines scaffold
samples were screened for their ability to decrease the 90%
effective concentration (EC90) of the known efflux pump
substrate, tetracycline, toward a tetracycline resistant strain of
P. aeruginosa (tetracycline alone EC90 = 82.5 µM). EC90s were
defined as the concentration required to produce 90% inhibition
of the test organism. The capacity for potentiation of all scaffolds
was determined by mathematical modeling to identify (and thus
exclude) those molecules that also possessed antibacterial activity
themselves (see Materials and Methods section “Statistical
Analysis of Checkerboard Assays” for details). Upon analysis, 17
libraries resulted in a potentiated tetracycline EC90 of ≥twofold,
whilst 6 resulted in a fold potentiation of ≥4 (Figure 1 and
Supplementary Table S2). A consideration with these studies
is that we wish to identify efflux pump inhibitors, rather than
compounds that have bacterial killing activity themselves. Upon
testing the top 17 libraries we determined that 7 of them,
including the 5 most active scaffolds, had individual antibacterial
activity. Of the remaining 10 libraries, 2229 (polyamines derived
from reduced acyl peptides) had the best potentiating effects
(>fourfold, tetracycline EC90 lowered to 21.03 µM), without
itself having antibacterial activity. For this reason, we prioritized
the 2229 polyamine scaffold for further assessment.
Lead Polyamine Efflux Inhibitor
Screening
To explore suitability of polyamine derivatives as efflux pump
inhibitors, a library of 188 individual compounds contained
within the Torrey Pines chemical collection were screened for
their ability to decrease the 50 and 90% effective concentration
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FIGURE 1 | Screening of combinatorial libraries to identify scaffolds that inhibit bacterial efflux pumps. The Torrey Pines scaffold libraries (TPL) were screened for
potentiation of tetracycline activity against a clinical tetracycline-resistant P. aeruginosa isolate 1419. Data is represented as fold potentiation, which is defined as the
EC90 tetracycline concentration (no TPL)/EC90 tetracycline concentration with TPL. In each assay, the TPL concentration used was 25 µg mL−1. The libraries
represented by a red bar displayed inhibition of bacterial growth themselves, in the absence of tetracycline, whilst blue bars represent libraries that display no
inhibition of bacterial growth. Positive (PAβN) and negative (10% DMF) control compounds were used, and are denoted by black bars. Note that only libraries
displaying twofold or greater potentiation are shown.
of tetracycline toward P. aeruginosa (Supplementary Table S3).
These studies were expanded to include EC50 determinations
as well as EC90 to provide depth to our structure activity
relationship analysis.
Upon analysis, 37 individual polyamines were found to inhibit
bacterial growth alone at or below the maximum concentration
tested 25 µg mL−1. Of the 151 remaining polyamines, 72
reduced the tetracycline EC50 by <twofold, 30 decreased the
tetracycline EC50 between twofold and fivefold, and 49 decreased
the tetracycline EC50 by ≥fivefold. From this latter group, 10
were also successful at decreasing the 90% effective concentration
by ≥fivefold. Four of the 10 most effective polyamines (247,
250, 266, 271) had an amine functionality at the R1 position,
S-methylbenzene at the R2 position, and ethylbenzene at the R3
position. Interestingly, both stereoisomers of methylbutylamine
(247 = S-N-methylbutylamine: 266 = R-N-methylbutylamine)
were found to create strong potentiation at the R1 position. From
the remaining six polyamines, three (314, 338, and 348) had
S-methylbenzene at the R1 position, an amine functionality at
the R2 position, and ethylbenzene at the R3 position; while three
(393, 414, and 453) had S-methylbenzene at the R1 and R2, and
varied aromatic groups at the R3 position; thus, lacking an amine
functionality at the R1 or R2 position. Although polyamines
393, 414, and 453 displayed promising fold-potentiation values,
these agents were not selected as lead agents when considering
that a large portion (24%) of polyamines with the R1 and R2
functionality defined by S-methylbenzene displayed antibacterial
activity themselves. In contrast, however, the majority (52%) of
polyamines with S-methylbenzene at the R2 and R3 positions
displayed ≥twofold potentiation of tetracycline activity without
displaying inhibition alone. Therefore, we prioritized polyamines
with amine functionalities at the R1 position (247, 250, 266,
271), as this was the most promising orientation for the
positive charge. In addition, while the 10 most potentiating
polyamines were shown to decrease the EC50 of tetracycline
from 47.8 µM to ≤9 µM, there were a subset of four agents
(247, 250, 271, 314) that were more effective at decreasing
the EC90 than the EC50 revealing their activity does not
plateau before 90% bacterial inhibition is achieved. Therefore,
we chose polyamines 247, 250, 266, 271, 314 from the 10
most potentiating polyamines to undergo secondary validation
assessment to explore their efflux pump inhibitor-like properties
(Figure 2).
Using dose response studies (Figure 3A and Supplementary
Figure S2A), we determined that the most effective lead was
compound 271, potentiating the tetracycline EC90 by 8.5-fold and
its EC50 by 8.2-fold (Table 1). With regards to the remaining
four compounds, we determined that 247 resulted in an 8.3-fold
decrease of the EC90 and a fivefold decrease of the EC50. Of note,
these two compounds are similar with S-methylbenzene at the
R2 position, and ethylbenzene at the R3 position, however, they
differ slightly at the R1 position (247 = S-N-methylbutylamine;
271 = R-N-propylamine). Additionally, compounds 250 and 266
both display a 7.8- and 5.8-fold potentiation of the tetracycline
EC90, respectively, with strong EC50 values of 7.0- and 6.8-fold
potentiation. Interestingly, 266 displayed more promising EC50
fold-potentiation than EC90, however this is a common feature
of competitive efflux pump inhibitor (Askoura et al., 2011);
indeed, our studies reveal a similar effect for the well described
molecules reserpine and PAβN (Table 1). Both 250 and 266
also have S-methylbenzene at the R2 position and ethylbenzene
at the R3 position similar to compounds 247 and 271, but
again vary at the R1 position (250 = S-ethylamine; 266 = R-N-
methylbutylamine). Compound 314 was found to have EC50 and
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FIGURE 2 | Structure of core polyamine scaffold (2229) and individual polyamine lead molecules.
FIGURE 3 | Polyamine lead agents potentiate the activity of unrelated antibiotic efflux substrates. P. aeruginosa (1419) cells were treated with polyamine molecules
at increasing concentrations, alongside tetracycline (A) or chloramphenicol (B). Shown is the fold potentiation of each antibiotic (EC90 values) as the efflux pump
inhibitor concentration was increased.
EC90, fold potentiation values of 5- and 7.5-fold, respectively.
Of note, 314 has an S-methylbenzene at the R1 position and an
amine functionality (this time propylamine) at the R2.
Polyamines Inhibit Efflux Pump Activity
for a Wide Range of Organisms and
Antibiotic Substrates
To confirm that the activity of our lead agents was not merely
confined to tetracycline, we next explored the potentiation
of an unrelated antibiotic efflux substrate, chloramphenicol
(Figure 3B and Supplementary Figure S2B). Each of the
polyamine agents again displayed an increase in the potentiation
of chloramphenicol EC90 in a dose responsive manner. Agent
266 displayed the highest potentiation values, although all
compounds performed in a markedly similar, and effective
manner. To determine if P. aeruginosa was the only organism
targeted by our polyamine lead molecules, we next performed
similar experiments with two other leading, and unrelated,
ESKAPE pathogens: A. baumannii and Methicillin Resistant
S. aureus (MRSA). It should be noted that in these studies, we
only used a single compound for each, for proof of principle, due
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TABLE 1 | Potentiation assessment of lead polyamine compounds.
MW EPI∗a TET+EPI∗b FP∗c TET+EPI#b FP#c
247 368.56 >25 9 5.0 12 8.3
250 340.51 >25 9 7.0 12 7.8
266 368.56 >25 9 6.8 16 5.8
271 354.53 >25 5 8.2 10 8.5
314 354.53 >25 9 5.0 12 7.5
Reserpine 608.68 >25 4 11.2 >50 1
PAβN 519.47 >25 0.7 65.5 11.63 8
All assays were performed in triplicate alongside no drug controls, known efflux
pump inhibitors (EPIs) reserpine and PAβN, and tetracycline alone controls (data
not shown due to repetitive values, average concentration for EC50 across all
replicates = 47.8 µM; EC90 = 82.5 µM). Molecular weight (MW) of all compounds is
displayed as grams mole−1. ∗50% effective concentrations (EC50). #90% effective
concentrations (EC90). aEPI is the inhibitory concentration of the individual Efflux
Pump Inhibitor (EPI) alone (µg mL−1). bTET+EPI is the respective EC tetracycline
(µM) in the presence of each compound. cFP is Fold Potentiation = EC tetracycline
+ EPI/EC tetracycline (no EPI).
to limited available material. For the former organism we used
lead molecule 271 and the antibiotic efflux substrate levofloxacin,
again revealing a dose response curve of antibiotic potentiation
as seen with P. aeruginosa (Figure 4A). When MRSA was
tested in a similar manner using the substrate chloramphenicol
and lead 247, we also noted marked potentiation of antibiotic
activity in a dose responsive manner (Figure 4B). As such, it
would appear that our polyamines are capable of potentiating
the activity of multiple antibiotic substrates, from a variety of
different classes, and toward both Gram-negative and Gram-
positive pathogens.
Polyamines Function via the Inhibition of
Bacterial Efflux Mechanisms
Following these promising results, we sought to validate our
findings using more direct means. Accordingly, the polyamines
were assessed using an ethidium bromide fluorescence assay
that has been widely used to identify efflux inhibitors (Renau
et al., 1999; Lomovskaya et al., 2001; Webber et al., 2013;
Blanchard et al., 2014; Vasudevan et al., 2014). This assay is a
well documented variation on ethidium bromide accumulation
assays, as it allows for a pre-incubation step to facilitate
accumulation, before compound treatment to measure efflux
(Raherison et al., 2002; Paixao et al., 2009). Fluorescence
of ethidium bromide occurs during intercalation with DNA;
thus, active efflux mechanisms decrease such fluorescence by
extruding ethidium bromide before it can interact with its
target. Thus, disruption of efflux pump activity leads to the
accumulation of intracellular ethidium bromide and a subsequent
increase in fluorescence over time compared to efflux proficient
cells. Importantly, when we treated P. aeruginosa with lead
polyamines, followed by a sub-lethal concentration of ethidium
bromide, we observed an increase in fluorescence (Figure 5A)
compared to no drug controls; indicating inhibition of efflux
systems. To determine if these effects are solely limited to
P. aeruginosa, we next tested other Gram-negative pathogens.
When these assays were repeated with A. baumannii, we observed
similar results (Figure 5B), indicating the broad-spectrum nature
of these agents. Furthermore, when we assayed the gram-
positive pathogen S. aureus, we again derived similar findings
(Supplementary Figure S3A).
To provide further direct evidence of efflux inhibition by our
lead compounds, we next tested their activity using strains with
varying efflux potential. As such, alongside our test P. aeruginosa
strain (1419) which has strong efflux capacity, we also tested an
efflux impaired strain of this same organism, 1418. The efflux
capacity of these two strains was determined using an ethidium
bromide agar assay that has been previously documented as a
measure of efflux capacity for bacterial strains (Supplementary
Figure S4; Martins et al., 2013). Here, we tested all 5 leads
against the two strains and the clinically relevant efflux antibiotic
substrate aztreonam (Figure 6A). Upon analysis we found that
all of our lead molecules were capable of effectively potentiating
the activity of aztreonam toward our test strain 1419, however
no such inhibition was seen for isolate 1418. Interestingly, we
observed strong activity correlation with these studies, as our two
best potentiators of tetracycline (271 and 250) were also the best
potentiators of aztreonam.
To ensure that these findings were not specific only to
P. aeruginosa, we next tested one of our lead polyamines, 247
(only 1 used due to limited available compound), against an
efflux deficient strain of MRSA. For this we used a mutant of the
major efflux pump NorA in the United States 300 background.
When tested, we observed that whilst our lead polyamine was able
to strongly potentiate chloramphenicol activity in the wild-type
strain, there was little potentiation observed in the norA knockout
(Figure 6B). The small amount of potentiation seen in the mutant
strain is likely a result of the fact that, although NorA is indeed the
major efflux pump in S. aureus, others also exist in this organism
(Costa et al., 2013). Importantly, the MRSA strain used in these
studies was different to those for our ethidium bromide analysis
(USA 300 vs. United States 100), presenting further evidence that
our molecules are not strain (or species) specific in their effects.
Collectively, these data suggest that our polyamine molecules are
not only effective inhibitors of bacterial efflux mechanisms, but
that these effects appear to be broad-spectrum in range.
Polyamines Act Competitively With PAβN
to Potentiate the Tetracycline Effective
Concentration
To further confirm the efflux pump inhibitor activity of
polyamine agents, we performed a checkerboard assessment to
determine the relationship between our front runner molecules
and the control compound PAβN. If our polyamine agents
inhibit a target other than efflux pumps, then combination
treatment would produce a synergistic action. However, if
the agents are both inhibiting efflux pumps, the result of
combination treatment would be antagonistic (Auerbach et al.,
2010; Goodman et al., 2011). Upon analysis we observed a clear
competitive interaction between PAβN and polyamine agents
in the presence of tetracycline (Supplementary Figure S5). This
further confirms that the polyamine agents are inhibiting efflux
pumps of bacterial species.
Frontiers in Microbiology | www.frontiersin.org 7 June 2018 | Volume 9 | Article 1301
fmicb-09-01301 June 12, 2018 Time: 16:8 # 8
Fleeman et al. Polyamines as EPIs
FIGURE 4 | Lead polyamines potentiate antibiotic activity toward other ESKAPE pathogen species. A. baumannii (1643) or MRSA (USA300) cells were treated with
the noted polyamine molecules at increasing concentrations, alongside levofloxacin (A) or chloramphenicol (B). Shown is the fold potentiation of each antibiotic
(EC90 values, blue bars) as the efflux pump inhibitor concentration was increased, and the concomitant decline in antibiotic MIC (EC90 values, red bars). Error bars
are shown ± SEM.
FIGURE 5 | Polyamine molecules have broad spectrum efflux pump inhibitor activity. P. aeruginosa (1419) (A) or A baumannii (1643) (B) cells were treated with a
sub-lethal concentration of ethidium bromide (25 µM) in combination with tetracycline, the known efflux inhibitor PAβN, lead polyamine agents at 25 µg mL−1, or
vehicle (10% DMF) (ND). Graphs demonstrate fluorescence after 90-min exposure displayed as relative fluorescent units. Error bars are shown ± SEM.
Polyamine Molecules Do Not Randomly
Depolarize Prokaryotic or Eukaryotic
Membranes
A number of efflux pump inhibitors discovered to date have been
shown to non-specifically inhibit efflux mechanisms through the
non-specific depolarization of charge across bacterial membranes
(Askoura et al., 2011; Webber et al., 2013). To determine if
such effects were true of our polyamines, we assessed membrane
depolarization using the molecular probe DiSC3. In cells with
normal membrane polarity, the bacterial membrane will quench
fluorescence of the DiSC3 dye. However, if the membrane is
depolarized, the dye is released, and fluorescence increases over
time. Our results reveal that the polyamines had minimal effect
on bacterial membranes, as they allowed for stabilization of
the quenched dye (Figure 7A). Whilst the positive control
nisin and PAβN treated cell membranes displayed a strong
increase in fluorescence, indicating membrane destabilization,
cells treated with chloramphenicol or solvent only (10% DMF)
decreased in florescence indicating a continued quenching of the
membrane dye. Polyamines treated cells displayed essentially no
change in fluorescence, revealing little to no depolarization when
compared to the known efflux inhibitor PAβN. To ensure there
is no depolarization of Gram-positive bacterial membranes we
repeated this experiment with S. aureus and observed a lack of
depolarization toward this species as well (Supplementary Figure
S3B). As such, these results are considered promising given that
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FIGURE 6 | Confirming efflux pump inhibition by polyamines using efflux deficient strains. (A) A P. aeruginosa proficient (1419) and deficient (1418) strain were
subjected to combination testing of the polyamines at 12.5 µg mL−1 and 1/2 X MIC of aztreonam. Fold potentiation was calculated by dividing the CFU mL−1 for
aztreonam only by the CFU mL−1 of the combined treatment groups. (B) Lead polyamine 247 was assessed for its ability to potentiate the activity of
chloramphenicol toward S. aureus strain United States 300 and its norA mutant. Shown is the potentiated chloramphenicol EC90 calculated as described in A. Error
bars are shown ± SEM.
FIGURE 7 | Polyamines do not destabilize prokaryotic or eukaryotic membranes. (A) Shown is the change in fluorescence of P. aeruginosa (1419) cells using a Disc3
dye assay. Data is presented as change in fluorescence before and after addition of leads compounds, PAβN, and nisin at 25 µg mL−1. (B) Calcium channel activity
assays to assess inhibition of calcium channel pumps in HEK 293 cells after the addition of polyamines 250, 266, 271 or the positive control verapamil at 25 µg
mL−1. Data is presented as change in fluorescence of cells before and after addition of the Fluo-4 dye. No drug (ND) and/or chloramphenicol (CM) were used as
negative controls. Error bars are shown ± SEM.
other, unrelated polyamines have been shown to have the capacity
to destabilize membranes by others (Katsu et al., 2002).
Another key consideration when developing efflux pump
inhibitors is their impact on eukaryotic efflux systems, as
many such molecules identified to date have non-specific effects
on mammalian ion transport systems as well (Van Bambeke
et al., 2006). This is of particular importance when testing
polyamines, as other, unrelated molecules of this class have been
shown to disrupt calcium release in bacterial cells as well as
eukaryotic cells (Katsu et al., 2002). As such, we tested the
effects of the polyamines in this regard against human embryonic
kidney epithelial cells (Hek293T), alongside the known, and
toxic efflux pump inhibitor, verapamil. In these studies, we
determined that our polyamine efflux inhibitors mirrored no
drug controls when assessed for their ability to interfere with
eukaryotic calcium channel activity (Figure 7B). Specifically,
lead compound treated cells exhibited increased fluorescence in
the presence of the Fluoro-4 dye, whilst verapamil decreased
fluorescence, representing the inhibition of calcium channel
activity. Thus, it would appear that our polyamines are not
only specific efflux pump inhibitors, but that their effects are
selective for prokaryotic membrane pumps, over their eukaryotic
counterparts.
Lead Polyamine Efflux Pump Inhibitors
Lack General Toxicity Toward Eukaryotic
Cells
Given the lack of effect of polyamines toward eukaryotic
ion channels, we next assessed general cytotoxicity toward
human cells. As such, polyamine lead compounds were tested
against both HepG2 and Hek293T cell lines using MTT assays
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FIGURE 8 | Lead polyamines lack general toxicity toward eukaryotic cells. Shown is the percent recovery of Hek293T cells (A) and HepG2 cells (B) when tested
using a MTT cytotoxicity assay following treatment with polyamine leads. Conversion of MTT to formazan was assessed and converted to percent recovery using
0.01% Triton 100× as 100% death, and no treatment (DMF) as 100% survival. These controls were used to calculate percent recovery, and to determine LD50s
(dotted line). Data is from at least three biological replicates, with error bars shown ± SEM.
(Figure 8). In so doing, we determined that front runners
247, 266, and 271 had extremely low toxicity toward Hek293T
cells. Specifically, when treated with 25 µg mL−1 of these
compounds, cells displayed 84, 72, and 75% recovery compared
to solvent only controls, whilst the known efflux pump inhibitor
PAβN returned only 63% cell viability. In support of this,
HepG2 cell recovery after treatment with 250, 314, or 271
generated similar results; even at the highest concentration
tested (again 25 µg mL−1) we observed 80, 77, and 74%
cell viability. In comparison, the known efflux inhibitor PAβN
tested at the same concentration allowed for 68% recovery
of HepG2 cells. The higher toxicity of PAβN was perhaps
unsurprising considering that this agent has been shown to
depolarize membranes at higher concentrations (Webber et al.,
2013).
Polyamine Efflux Pump Inhibitors
Strongly Enhance the Bactericidal
Activity of Tetracycline
We next set out to explore the impact of polyamines on the
bactericidal effects of tetracycline. The rationale for this was
that, although tetracycline is a bacteriostatic antibiotic, it is
known to be bactericidal at high concentrations (Pankey and
Sabath, 2004). Treatment with our polyamines alone at 25 µg
mL−1 resulted in minimal impact to bacterial viability, with
≥95% of cells recovered for all compounds, in contrast to PAβN
which returned only 76% viability at the same concentration.
Tetracycline treatment alone at 12, 25, and 50 µM allowed
for 53, 35, and 1% respective bacterial recovery. However,
combination treatment with tetracycline and the MPC of
all lead agents resulted in decreased bacterial viability. For
example, combination treatment with 12 µM of tetracycline
and polyamine 266 displayed the greatest decrease in bacterial
viability, similar to the control PAβN. Specifically, the percent
recovery decreased to 0.76 and 0.79% when treated with 266
or polyamine PaβN, respectively (Figure 9). Although not as
impressive as 266 and PAβN, combination treatment with
polyamines 247, 250, 271, and 314 resulted in 2.9, 2.2, 2, and 5.3%
recovery, respectively. Interestingly, we found that increasing
tetracycline alone from 12 to 25 µM resulted in 17.8% less
recovery, however combination treatment revealed a significant
decrease in bacterial viability. In combination with 25 µM
tetracycline, our polyamines appeared to outperform PAβN as
they allowed for ≤0.08% recovery, whilst combination treatment
with PAβN allowed for 0.2% recovery. Furthermore, 50 µM
treatment with tetracycline decreased bacterial viability to 1%
alone, however this was drastically decreased with combination
efflux pump inhibitor treatment. Specifically, polyamines 250,
266, and 314 resulted in the greatest decrease in bacterial
recovery, allowing for 0.01% recovery. This was marginally less
recovery than that of the control PAβN and polyamine 271, which
allowed for 0.02% recovery. Polyamine 247 displayed the least
decrease in viability with combination treatment, although it still
decreased bacterial recovery to 0.04%. Given that bactericidal
activity is often preferred to bacteriostatic effects, particularly
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FIGURE 9 | Polyamine efflux pump inhibitors strongly enhance the
bactericidal activity of tetracycline. P. aeruginosa (1419) cells were treated with
tetracycline at 0, 12, 25, and 50 µM in combination with no drug (ND), or 247,
250, 266, 271, 314 and PAβN at 25 µg mL−1. The dotted line on the graph
denotes 90% bactericidal activity. Data is from at least three biological
replicates, with error bars shown ± SEM.
FIGURE 10 | Polyamine potentiation of tetracycline activity limits biofilm
recovery by P. aeruginosa. The lead polyamine agents were tested for their
ability to impact viability of a pre-formed biofilm. P. aeruginosa (1419) cells
were treated with tetracycline at 0, 12, 25, and 50 µM in combination with no
drug (ND), or 247, 250, 266, 271, 314 and PAβN at 25 µg mL−1. The dotted
line on the graph denotes 90% reduction in cell viability within biofilms. Data is
from at least three biological replicates, with error bars shown ± SEM.
for immunocompromised patients, these findings are considered
encouraging.
Polyamine Potentiation of Tetracycline
Activity Reduces Biofilms by
P. aeruginosa
Biofilm formation is responsible for chronic, drug-resistant
bacterial infections by a number of pathogens, and particularly
P. aeruginosa. Considering the strong potentiation of tetracycline
activity engendered by our lead agents, we next chose to
determine if they had significant impact on the viability of cells
within biofilms. Treatment with efflux pump inhibitors 247, 250,
266, 271, and 314 alone at 25 µg mL−1 (MPC), respectively,
resulted in negligible impact on biofilm viability, with 99.99%
of cells recovered for all compounds other than 266 which
allowed for 92% recovery. Similarly, tetracycline treatment alone
at 12 and 25 µM had little impact, allowing for 88 and 84%
biofilm recovery, respectively (Figure 10); only at 50 µM were
more pronounced effects observed, with only 9% cells recovered.
Combination treatment with 12 µM tetracycline and the MPC
of all lead agents resulted in a significant decrease in biofilm
recovery, however, with viability of 9.1–11% observed for 271,
247, 266, and 314, respectively. Combination treatment with lead
agent 250 resulted in a slightly higher biofilm recovery of 21%,
however still improving tetracycline alone biofilm eradication
by 67%. Increasing tetracycline concentration by itself from 12
to 25 µM only resulted in 4% more eradication, however in
combination with our efflux pump inhibitors, recovery decreased
to 0.5 and 0.6% for 271 and 247, respectively. Similarly,
treatment with agents 266, 250, and 314 resulted in 1% biofilm
recovery. This biofilm eradication was particularly impressive
when compared to the activity of the positive control PAβN (7%
recovery at 25 µM tetracycline). Furthermore, at the highest
tetracycline concentration (50 µM) combination treatment with
PaβN produced a 1% biofilm recovery while agents 271 and
247 allowed for only 0.2% recovery. Treatment with agent
250, 266, and 314 resulted in similar recovery of 0.5, 0.6,
and 0.6%, respectively. These results suggest a potential benefit
of combination treatment with our polyamine molecules and
known efflux antibiotics to reduce biofilms.
DISCUSSION
Antibiotic resistance is a developing crisis in clinical settings,
with an increasing number of bacterial isolates discovered each
year that are resistant to our therapeutic arsenal (Rossolini et al.,
2014; Ventola, 2015). Efflux pumps are a major contributor to
multi-drug resistance because they help circumvent the action
of a broad range of substrates that includes multiple antibiotics
classes (Askoura et al., 2011; Handzlik et al., 2013; Soto, 2013).
This is compounded by the observation that most bacterial
species utilize multiple efflux pumps with an overlapping range
of substrates (Weinstein and Hooper, 2005; Van Bambeke et al.,
2006; Sun et al., 2014). With this considered, the development of
broadly active efflux pump inhibitors is considered desirable, so
as to focus on the reclamation or reactivation of a wide swath
of existing therapeutics (Masuda et al., 2000; Lomovskaya et al.,
2001; Kumar and Varela, 2012; Blanchard et al., 2014).
The potentiating modeling utilized in this study allowed for
the identification of polyamines that increased the effectiveness
of tetracycline without displaying any toxic effects themselves.
This highlights the importance of potentiation modeling for the
identification of anti-resistance agents, as opposed to synergistic
agents that display antimicrobial properties as well. Potentiation
modeling is a more advantageous approach to identifying
adjuvant agents because synergy assessment is reliant on the
therapeutic agent having antibacterial activity (Hoel, 1987). Efflux
pump inhibitors identified using synergistic activities, i.e., PaβN,
have been unsuccessful due to off-target effects, causing bacterial
growth inhibition (Renau et al., 1999; Lomovskaya et al., 2001;
Webber et al., 2013). Importantly, in support of our approach,
it has been shown that the concomitant treatment with an
antibiotic and adjuvant agent that blocks the mechanism of
resistance toward that antibiotic, but that has no antimicrobial
properties itself, can lead to decreased resistance development
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(Olofsson and Cars, 2007; Worthington and Melander, 2013).
Although a subset of polyamines was discovered during our
screening with antimicrobial effect themselves, their structure
activity relationship was taken into consideration during lead
polyamine selection as discussed in detail below, and these
molecules were eliminated from further consideration.
Efflux pump discovery began with the finding that efflux
of host antimicrobial polyamines by the S. aureus Tet38 efflux
pump facilitated skin colonization, and the ability to survive
within an abscess environment (Truong-Bolduc et al., 2013).
Beginning with the initial development of polyamine tetracycline
derivatives to increase the effectiveness of tetracycline, (Nelson
et al., 1993, 1994; Nelson and Levy, 1999), polyamine molecules
have been shown to increase the therapeutic potential of common
antibiotics (Vazquez-Laslop, 1997; Kwon and Lu, 2007; Rockey
et al., 2013). Kwon and Lu (2007) revealed the endogenous
polyamines spermidine and spermine, found within all living
cells, when administered exogenously were effective at increasing
the therapeutic potential of β-lactams toward Gram-negative
organisms by blocking the outer membrane porin OprD. They
also found these natural polyamines were shown to potentiate
activity of chloramphenicol and β-lactams toward Escherichia
coli and S. aureus (Kwon and Lu, 2007). Similarly, in Bacillus
subtilis, the efflux pump Blt is dedicated to the extrusion of
spermidine, however it has also been shown to opportunistically
bind to other polyamine molecules (Vazquez-Laslop, 1997).
Furthermore, in Mycobacterium tuberculosis, there is a significant
increase in the effectiveness of fluoroquinolones administered
alongside polyamine treatment (Rockey et al., 2013). Conversely,
it has been shown that natural polyamines and PaβN have toxicity
associated with their amine substituents, therefore care must be
taken when developing therapeutics of this nature (Opperman
et al., 2013; Pegg, 2013). Even though this toxicity is known,
amine molecules continue to be pursued to target multiple disease
states (Goldberg and Rajfer, 1982; Thomas and Thomas, 2001;
Bogatcheva et al., 2006; de Jonge et al., 2015; Li et al., 2015a).
Moreover, there are many therapeutics in use in clinics today
that contain amines, such as aminoglycosides; thus, despite their
potential for toxicity, approaches have been used successful to
decrease these effects (Poulikakos and Falagas, 2013). Indeed,
the FDA recently approved Zerbaxa (ceftolozane/tazobactam) for
treatment of β-lactamase producing enteric species. Importantly,
the ceftolozane component of this therapeutic combination
contains multiple amine substituents (Fernandes and Martens,
2017). These studies collectively reveal the therapeutic potential
of polyamine molecules despite the potential for compounds of
this class to display unwanted side-effects.
The polyamine agents discovered in this study were successful
in not only returning the effectiveness of tetracycline but
also an unrelated antibiotic efflux substrate, chloramphenicol.
Importantly, this finding reveals that our polyamines are not
just allowing for the increased effectiveness of one, but multiple
commercial antibiotics from a broad range of different classes.
This finding suggests that the polyamines discovered in our
study inhibit through direct competitive inhibition (Kourtesi,
2013). This mechanism of efflux inhibition capitalizes on the
broad-spectrum binding affinity of efflux pumps by blocking
the substrate binding extrusion protomer on the distal binding
site (Nikaido and Pages, 2012; Opperman and Nguyen, 2015).
Interestingly, tetracycline binds to the “groove” region of the
binding pocket in the binding protomer, while chloramphenicol
binds to the deeper “cave” region. Covalent binding to this
“cave” region is the ultimate in efflux inhibition as it causes the
binding pocket to collapse and become non-functional, therefore
inhibiting multiple substrates from binding (Nikaido and Pages,
2012).
Notably, the direct measurement of ethidium bromide
fluorescence revealed our polyamines inhibit the efflux pumps
of Gram-negative species P. aeruginosa and A. baumannii, as
well as the Gram-positive organism S. aureus. There are five
families of efflux pumps: MFS, ABC, SMR, MATE, and RND.
The first four are used by all bacterial species, whilst RND
efflux pumps are largely used by Gram-negative species (Sun
et al., 2014). The RND family is the main Gram-negative efflux
system suggesting that, as our polyamine agents are active in
both Gram-positive and -negative organisms, they are likely
inhibiting more than one family of efflux pumps (although it
is acknowledged that some Gram-positive organisms do harbor
them). This can be attributed to the competitive inhibition nature
of efflux pumps inhibitors that harnesses the broad substrate
recognition of efflux pumps for more effective efflux inhibition
in multiple organisms. For example, the efflux pump families
of RND, ABC, SMR, and MFS all recognize substrates with
polycationic properties (Kumar and Pooja Patial, 2016). Further
to this, RND pumps found in P. aeruginosa and E. coli recognize
and extrude tetracycline, while ABC and SMR pumps in S. aureus
also expel this same antibiotic (Kumar and Pooja Patial, 2016).
This would explain the activity of the previously identified efflux
pump inhibitor baicalein, which is derived from the plant Thymus
vulgaris, and has been found to potentiate tetracycline activity
by blocking the MFS family TetK efflux pumps of E. coli and
S. aureus (Wax et al., 2001; Fujita et al., 2005; Kumar and Pooja
Patial, 2016). Moreover, our polyamine efflux pump inhibitors
appear to be acting in a competitive manner with the positive
control PAβN, potentially competing for the same substrate
binding pocket (Webber et al., 2013; Venter et al., 2015). In
fact, our polyamines resemble the known efflux pump inhibitor
PAβN more so than the other well-known efflux pump inhibitor
1-(1-naphthylmethyl)-piperazine (NMP), which is shown not
to potentiate antibiotic activity toward P. aeruginosa (Coban
et al., 2009). This would explain the activity of the recent
identification of a pyranopyridine inhibitor, MBX2319 that was
designed based on NMP and found to have potent activity toward
Enterobacteriaceae but little activity toward P. aeruginosa (Sjuts
et al., 2016). However, a pyridopyrimidine scaffold discovered
by Nakashima et al. (2013), with more similarities to PAβN
was found to potentiate chloramphenicol and tetracycline and
further revealed to bind the distal pocket of both P. aeruginosa
MexAB and E. coli AcrB, whereas MBX2319 was specific to AcrB
(Venter et al., 2015). However, even with the apparent binding
differences observed in recent studies, MexAB of P. aeruginosa
is still a close homolog of AcrB and has the same dependence
on outer membrane stability as all RND efflux pumps do (Li
et al., 2015b). Therefore, this dependence on membrane stability
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necessitates a rigorous analysis of membrane disruption for all
agents (polyamine or otherwise) being developed as efflux pump
inhibitors.
Importantly, we observed our polyamines did not have
deleterious effects on bacterial cell membranes, as is seen for
the known efflux pump inhibitor PAβN (Webber et al., 2013).
Many efflux pump inhibitors discovered to date have been found
to cause disruption of the bacterial cell membrane leading to
their ineffectiveness as therapeutic agents (Misra and Bavro,
2009; Machado et al., 2017). Disruption of the bacterial cell
membrane causes inhibition of efflux through a secondary effect
of membrane depolarization, leading to inhibitory activity alone,
and the common identification of false positive, non-specific
efflux pump inhibitors (Cornwell et al., 1987; Webber et al., 2013;
Li et al., 2015b). Considering the fact that polyamines have been
shown to disrupt bacterial membranes it is, perhaps surprising
that our polyamines do not disturb bacterial membranes,
however the potentiation modeling used herein specifically
sought to eliminate the selection of false positive efflux pump
inhibitors. In our analysis we did identify polyamines, derived
from our scaffold, with antimicrobial activity that was eliminated
from study due to unwanted, off-target effects. Regarding our
lead agents, at least at the maximum concentrations tested,
we observed little to no membrane destabilization for MRSA
and P. aeruginosa. We note, however, that other polyamine
molecules do have the potential for this activity, thus these types
of studies will be an important part of future development for our
frontrunners. The identification of 37 polyamines that inhibited
bacterial viability themselves, although less than ideal, lead to
knowledge of a structure activity relationship for efflux pump
specificity. Those polyamines found to inhibit bacterial viability
themselves may be disturbing the cellular membrane based on the
position of positive charges within their structure. Our analysis
revealed 24% of the polyamines (26 out of 103) with R1 and R2
both defined by S-methylbenzene lead to antibacterial activity,
while only 7% (4 out of 60) that have S-methylbenzene at R2 and
R3, and 12% (7 out of 60) that have S-methylbenzene at R1 and
R3, had antibacterial activity. With this knowledge, we focused
our attention on compounds that had no antibacterial activity
themselves to avoid selecting membrane depolarizing agents.
In the future development of our molecules, iterative structure
activity relationship studies will ensure bias away from such
unwanted activity, and focus on harnessing only the positive,
efflux pump inhibiting effects observed for our lead molecules.
To increase our confidence in the specificity of the polyamines
discovered herein, we demonstrate that they have limited toxicity
toward two human cell lines and no inhibitory effects on
the eukaryotic Ca2+ channel activity of human kidney cells.
To date, many efflux pump inhibitors (such as verapamil)
have been shown to have non-specific inhibition of eukaryotic
transporters, and therefore create unwanted side effects as
therapeutic agents (Lomovskaya et al., 2001; Ughachukwu and
Unekwe, 2012; Amin, 2013; Lebeaux et al., 2013). Verapamil is
a non-specific inhibitor of calcium channels, found to also inhibit
the function of P-glycoprotein ABC transporters in mammalian
cells (Andersen et al., 2006). This inhibitor was found to have
in vitro function as a bacterial efflux inhibitor, however due
to its general toxicity, the use of this compound is limited to
angina, hypertension, and cardiac arrhythmia (Andersen et al.,
2006; Gupta et al., 2013). This assessment is extremely important
for our polyamines as calcium release has also been observed
from polyamines on bacterial cells (Katsu et al., 2002). With
limited toxicity and secondary effects, the polyamine efflux pump
inhibitors discovered in our study appear to have more favorable
characteristics than others previously discovered, suggesting
promising potential as adjuvant agents.
Taken together, the polyamines discovered in this study have
potential as therapeutic adjuvants to rescue the effects of multiple
antibiotics toward both Gram-positive and Gram-negative
species. They appear to be acting in a specific manner and have
none of the undesirable membrane targeting characteristics of
previously developed efflux pump inhibitors. As such, we suggest
that the polyamines developed herein are a promising scaffold for
further development of anti-resistance agents to help alleviate the
burden of multi-drug resistant bacterial pathogens.
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